← Back
Data updated: Mar 10, 2026
INTAS PHARMS USA
Oncology
INTAS PHARMS USA is a generic drug manufacturer focused on Oncology.
2017
Since
1
Drugs
-
Trials
13
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
IRINOTECAN HYDROCHLORIDE 2025-08-20
Labeling
IRINOTECAN HYDROCHLORIDE 2025-05-23
Labeling
IRINOTECAN HYDROCHLORIDE 2025-05-23
Labeling
IRINOTECAN HYDROCHLORIDE 2025-05-23
Labeling
IRINOTECAN HYDROCHLORIDE 2025-05-23
Labeling
IRINOTECAN HYDROCHLORIDE 2025-05-09
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 100%
1 drugs
Pipeline Strength Pro
Loading...
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2017-08-31
- Latest
- 2025-05-02
- Applications
- 2